Cáncer de útero

  1. Varela Pose, V. 1
  2. Cebey López, V. 1
  3. Pérez Martelo, M. 1
  4. Mateos González, M. 1
  5. Cueva Bañuelos, J.F. 1
  1. 1 Servicio de Oncología Médica y Grupo de Oncología Médica Traslacional, Hospital Clínico Universitario e Instituto de Investigación Sanitaria-CIBERONC, Santiago de Compostela, La Coruña, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades oncológicas (IV)Melanoma, cáncer de mama y tumores ginecológicos

Series: 13

Issue: 27

Pages: 1527-1532

Type: Article

DOI: 10.1016/J.MED.2021.03.004 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Sustainable development goals

Abstract

Endometrial cancer is the most frequent gynecologic tumor in our setting. The majority of cases are diagnosed in women older than 50 years of age. Type 1 endometrial cancer is the most frequent. Hormonal factors, specifically prolonged exposure to estrogen, are the main risk factor for developing its precursor lesion, endometrial hyperplasia, and its later progression to adenocarcinoma. Abnormal uterine bleeding is the most common symptom and occurs in the majority of patients who are already in the early stages of endometrial cancer. Therefore, its presence must be ruled out in all cases of abnormal bleeding. The initial imaging test of choice is a transvaginal ultrasound. An endometrial biopsy is necessary for its histological confirmation. The main prognostic factor of endometrial cancer is postsurgical staging. Surgery is the fundamental pillar of the treatment of this pathology. Chemotherapy and radiotherapy play an important role as adjuvant treatment of high-risk, locally advanced tumors. In metastatic disease, treatment is mainly based on palliative chemotherapy, although in select patients, hormone therapy is a reasonable option.

Bibliographic References

  • Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
  • Global Cancer Observatory [Internet]. Lyon: Global Cancer Observatory; c2018-20 Cancer Today.
  • Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, et al. ESMO Guidelines Working Group. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol. 2013;24 Suppl 6:vi33-8.
  • Soliman PT, Oh JC, Schmeler KM, Sun CC, Slomovitz BM, Gershenson DM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575-80.
  • Constantine GD, Kessler G, Graham S, Goldstein SR. Increased incidence of endometrial cancer following the women’s health initiative: an assessment of risk factors. J Womens Health (Larch). 2019;28(2):237-43.
  • Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control. 2010;21(11):1851-6.
  • National Comprehensive Cancer Network (NCCN). Genetic/Familial High Risk Assessment: colorrectal. version 1.2020.
  • Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-7.
  • Matias Guiu X, Prat J. Molecular pathology of endometrial carcinoma. Histopathology. 2013;62:111-23.
  • Cancer Genome Atlas Research Network. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
  • Clarke MA, Long BJ, del Mar Morillo A, Arbyn M, Bakkum Gamez JN, Wentzensen N. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta analysis. JAMA Intern Med. 2018;178(9):1210-22.
  • Chu CS, Lilie LL, Rubin SC. Gynecologic cancers. Cancer of the uterine body. En: Devita V, Lawrence T, Roseberg S, eds. DeVita, Hellman, and Rosenberg’s Cancer Principles and Practice of Oncology. Vol 2. 8th ed. Philadelphia: Wolters Kluwer; 2008. p.1544-89.
  • Santaballa A, Matías Guiu X, Redondo A, Carballo N, Gil M, Gómez C, et al. SEOM clinical guidelines for endometrial cancer (2017). Clin Transl Oncol. 2018;20(1):29-37.
  • Walker JL, Piedmonte MR, Spirtos NM, Eisenkop SM, Schlaerth JB, Mannel RS, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331-6.
  • Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta analysis. Gynecol Oncol. 2010;118(1):14-8.
  • Del Carmen MG, Boruta DM 2nd, Schorge JO. Recurrent endometrial cancer. Clin Obstet Gynecol. 2011;54(2):266-77.
  • Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel long term follow up. Int J Gynecol Cancer. 2008;18(4):803-8.
  • Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open label, single arm, phase 2 trial. Lancet Oncol. 2019;20(5):711-718.
  • Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17(5):964-78.
  • Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W; Gynecologic Oncology Group study. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(1):10-4.
  • Lorusso D, Ferrandina G, Colombo N, Pignata S, Pietragalla A, Sonetto C, et al. Carboplatin paclitaxel compared to Carboplatin Paclitaxel Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 A randomized phase II trial. Gynecol Oncol. 2019;155(3):406-12.
  • Aghajanian C, Sill MW, Darcy KM, Greer B, McMeekin DS, Rose PG, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259-65.
  • Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, et al. Randomized Phase II Trial of Carboplatin Paclitaxel Versus Carboplatin Paclitaxel Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018;36(20):2044-51.
Data source: Dialnet